RxDoctor Payments DataLook up a doctor →

Sunita Godiwala

Family Medicine · Holden, MANPI 1407838188

Payments from drug & device makers

$13,476in general payments, 2019–2025

Across 792 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$886
  • Novartis$862
  • Pfizer$815
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$699
  • plus $6K from 33 others

What the payments were for

  • Consulting fees$1201%
  • Speaking & faculty fees$5704%
  • Food & beverage$12,76795%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,476 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$198,036
Medicare patients
425
Services billed
1,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$87,699
MounjaroTirzepatide25$32,476
TrulicityDulaglutide19$30,431
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$22,792
JardianceEmpagliflozin18$20,917
XareltoRivaroxaban22$19,917
JanuviaSitagliptin Phosphate11$16,650
Bydureon BciseExenatide Microspheres13$10,504
Atorvastatin Calcium447$6,311
Colesevelam Hcl14$5,787
Rosuvastatin Calcium130$4,132
Metoprolol Succinate200$3,295
Omeprazole177$2,525
Albuterol Sulfate HfaAlbuterol Sulfate90$2,522
Olmesartan Medoxomil45$2,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$815$87,69974 claims
Lilly USA, LLCMounjaro, Trulicity$606$62,90744 claims
GSKTrelegy Ellipta$563$22,79218 claims
Boehringer IngelheimJardiance$416$20,91718 claims
Johnson & JohnsonXarelto$581$19,91722 claims
MerckJanuvia$191$16,65011 claims
AbbVieSynthroid$1,587$1,70437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Holden

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →